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Backgrounds: Stroke is a main cause of morbidity and mortality around the world, 
followed by cardiovascular disease. Up to date, recombinant tissue plasminogen 
activator (r-tPA) administration intravenously is the only FDA-approved therapy for 
acute ischemic stroke. Protein-tyrosine phosphatase-1B (PTP1B) is a member from 
PTP family and negatively regulates the insulin and leptin signaling pathways. Akt 
phosphorylation mediates a protective effect against ischemic injury. Previously, we 
reported that the non-selective PTP1B inhibitor, sodium orthovanadate, could rescue 
neurons from delayed neuronal death during brain ischemia. Recently, a new PTP1B 
inhibitor (KY-226) was developed to elicit anti-diabetic and anti-obesity effects via 
enhancement of insulin signaling (IC50 = 0.25 µM) (Fig.1). KY-226 was reported to 
bind to the allosteric sites of PTP1B to act as a non-competitive inhibitor (Ki = 0.35 
µM). However, the role of KY-226 on cerebral ischemia in mice is unknown. 
 
Fig.1 The chemical structure of KY-226. 
 
Methods: In vivo, we produced a murine model named transient middle cerebral 
artery occlusion (tMCAO) in ICR mice for 2 h. KY-226 (1, 5, 10, 30 mg/kg, dissolved 
in 10% 1-methyl-2-pyrrolidinone, 5% mixed solution (Cremaphor EL with ethanol 
1:1) and ddH2O) was administered to mice intraperitoneally 30 min after reperfusion. 
To assess Akt or ERK involvement, wortmannin (i.c.v.) or U0126 (i.v.), selective 
inhibitors of PI3K and ERK, respectively, were administered to mice 30 min before 
ischemia. 24 h after reperfusion, the infarct size and blood-brain barrier (BBB) 
permeability were measured by TTC and Evans Blue (EB) staining. Western blot and 
immunofluorescent analysis were used to examine the expression of Akt/eNOS, 
extracellular signal-regulated kinase (ERK), and proteins related to reactive oxygen 
species (ROS) levels and tight junction (TJ) function in ischemic brain in mice. ZO-1 
mRNA level was measured with real time-PCR. 
In vitro studies, bEnd.3 cells were stimulated with lipopolysaccharide (LPS) to induce 
inflammation and BBB disruption. 24 h after LPS or/with KY-226 treatment, the 
activity of ZO-1 promoter was measured with dual-luciferase reporter assay system. 
ZO-1, Akt, and forhead box protein O1 (FoxO1) proteins were tested by western blot. 
Results: Results showed that KY-226 was able to enter the bloodstream, showing a 
slight increase in plasma concentrations in control mice 30 min after injection (tmax = 
0.5 ± 0.14 h; Cmax = 71.64 ± 4.41 μM). Although KY-226 permeability was poor 
through the BBB of sham mice, it could penetrate through the BBB of mice after I/R 
insult. Intraperitoneal KY-226 administration elicited dose-dependent reductions in 
infarcted brain areas (Fig.2) and improved neurological deficits. The neuroprotective 
effects of KY-266 were obtained when administered within 0.5 h after reperfusion. 
KY-226 (10 mg/kg) also restored reduced Akt phosphorylation and eNOS 
phosphorylation (S1177) levels following I/R insult. Moreover, 10 mg/kg of KY-226 
improved I/R-induced decreased ERK phosphorylation. Furthermore, KY-226 
attenuated the generation of ROS in the cortex of mice. Activation of Akt and ERK 
possibly underlie the neuroprotective mechanism of KY-226. 
In addition, compared with vehicle group, KY-226 treatment could prevent BBB 
breakdown and inhibit EB leakage, remarkably attenuate the reductions in TJ proteins 
expression after reperfusion. KY-226 treatment restored ZO-1 mRNA levels 
post-reperfusion. Pre-administration with Akt and ERK inhibitor, wortmannin and 
U0126, could block the protective effects of KY-226 on ZO-1 protein and mRNA 
reduction in I/R insult in mice. In bEnd.3 cells, LPS treatment induced reduction on 
ZO-1 mRNA and protein levels. KY-226 treatment significantly restored both ZO-1 
mRNA and protein levels reduced by LPS (Fig.3). Furthermore, KY-226 treatment 
restored Akt phosphorylation (T308) and its downstream target FoxO1 protein 
phosphorylation (S256) in bEnd.3 cells. FoxO1 overexpression attenuated the activity 
of ZO-1 promoter, which could be ameliorated by KY-226 treatment. Collectively, we 
demonstrate that KY-226 protects BBB integrity by restoration of TJ proteins, an 
effect partly mediated by Akt/FoxO1 pathway activation.  
 
Fig.2 KY-226 reduced the ischemia/reperfusion injury in vivo. 
 
 
Fig.3 KY-226 prevented lipopolysaccharide (LPS)-induced tight junction (TJ) 
disruption in bEnd.3 cells. 
 
Conclusions: KY-226, a novel PTP1B inhibitor, exhibits neuroprotective and 
anti-oxidative effects via activating Akt/eNOS and ERK signaling pathway in 
ischemic mice. Moreover, KY-226 could upregulate ZO-1 expression through 
Akt/FoxO1 signaling pathway to maintain the BBB integrity in ischemic stroke and 
LPS treatment. KY-226 is expected to be a therapeutic candidate for ischemic stroke 
(Fig.4). 
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Fig.4 A scheme for the proposed mechanisms underlying the protective effects of 
KY-226 on the blood-brain barrier (BBB) in ischemia/reperfusion (I/R) or 
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選択的 PTP1B 阻害薬、KY-226 が開発された。本研究では中大脳閉塞一過性脳虚血（以下
tMCAO）マウスモデルを用いて、KY-226 の神経保護作用とそのメカニズムについて追究




にした。さらに、4) KY-226 による脳毛細血管の保護作用には Akt および細胞外シグナル
活性化キナーゼ（ERK）の活性化による血管内皮細胞接合蛋白質 ZO-1 の発現が関与する
こと、5) Z0-1 の発現には Akt 活性化による転写因子 FoxO1 の抑制が関与することを明ら
かにした。今後は、ERK の活性化が ZO-1 の発現に関与するか検討する必要がある。脳移
行性を高めた KY-226 誘導体を創製することで新規脳保護薬として期待できる。 
 以上、本研究では新規 PTP1B 阻害薬 KY-226 が脳内で Akt と ERK を活性化することによ
り、脳毛細血管（血液脳関門）の障害を抑制することにより、脳梗塞による脳障害を抑制
することとそのメカニズムの一つを明らかにした。臨床に応用可能な脳保護薬はないこと、
本薬剤が糖尿病治療効果を有することから、今後の臨床開発の可能性を示した点で大いに
評価できる。 
 よって，本論文は博士（薬科学）の学位論文として合格と認める。 
